Mankind Pharma Limited
MANKIND
Rangering i aksjer
#2064
Mankind Pharma Limited specializes in the development, manufacturing, and... Mankind Pharma Limited specializes in the development, manufacturing, and marketing of a broad range of pharmaceutical medications and consumer health goods. Operating predominantly in India, the company also caters to international markets. Its pharmaceutical division focuses on both acute and chronic therapeutic areas, encompassing a wide spectrum of medical conditions such as infectious diseases, cardiovascular ailments, gastrointestinal disorders, diabetes, dermatology, pain management, neuro/CNS issues, nutritional support (vitamins/minerals), and respiratory problems. Complementing its pharmaceutical portfolio, the consumer healthcare segment offers diverse products, including condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. Key brands under its umbrella include Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar. Furthermore, the company's business activities are diversified, extending to the trading and export of pharmaceutical and healthcare products, as well as the manufacturing of various goods such as packaging materials, ayurvedic products, bulk drugs, and general consumer items. Mankind Pharma also holds interests in real estate, leasing, hospitality, and IT services. Established in 1986, Mankind Pharma Limited maintains its headquarters in New Delhi, India.
Aksjekurs
$24.08
Markedsverdi
$9.95B
Endring (1 dag)
-4.09%
Endring (1 år)
-13.33%
Land
IN
Handel Mankind Pharma Limited (MANKIND)
Kategori
Healthcare
P/E-forhold for Mankind Pharma Limited (MANKIND)
P/E-forhold per October 2026 TTM: 45.98
Ifølge Mankind Pharma Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 45.98. Ved slutten av 2025 hadde selskapet en P/E på 49.99.
P/E-forholdshistorikk for Mankind Pharma Limited fra 2019 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 45.98 | -8.02% |
| 2025 | 49.99 | 3.26% |
| 2024 | 48.41 | 8.92% |
| 2023 | 44.45 | 11.83% |
| 2022 | 39.75 | -11.72% |
| 2021 | 45.02 | -18.57% |
| 2020 | 55.29 | -43.86% |
| 2019 | 98.48 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 23.30 | -49.33% |
DE
|
|
| - | - |
DE
|
|
| 55.58 | 20.87% |
JP
|
|
| 61.13 | 32.95% |
CH
|
|
| 34.96 | -23.97% |
IN
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.